{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T09:33:36Z","timestamp":1740130416751,"version":"3.37.3"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T00:00:00Z","timestamp":1726531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>During the COVID-19 pandemic period, many patients who required outpatient chemotherapy developed COVID-19, requiring chemotherapy interruption. However, there are no clear guidelines regarding the safe timing for restarting chemotherapy. We conducted a retrospective study to assess when such patients can safely recommence chemotherapy. Of the 40 patients included in this study, 34 restarted anticancer drug therapy after COVID-19 infection. Six patients, four with multiple myeloma, and one each with follicular lymphoma and glioma, remained SARS-CoV-2 antigen positive &amp;gt;20\u00a0days after COVID-19 onset. Multiple myeloma patients recorded significantly higher frequencies of SARS-CoV-2 antigen positivity &amp;gt;20\u00a0days after COVID-19 onset compared with solid tumor patients, with no significant differences in the frequency of SARS-CoV-2 positivity during 5\u201320\u00a0days from COVID-19 onset between them. According to our data, most solid tumor patients achieved SARS-CoV-2 antigen negativity after 20\u00a0days from COVID-19 onset. On the other hand, multiple myeloma patients might need serial antigen tests before restarting anticancer therapy in the outpatient chemotherapy setting.<\/jats:p>","DOI":"10.1093\/jjco\/hyae129","type":"journal-article","created":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T17:04:23Z","timestamp":1726592663000},"page":"80-86","source":"Crossref","is-referenced-by-count":0,"title":["COVID-19 in patients receiving treatment at an outpatient chemotherapy unit"],"prefix":"10.1093","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-9103-2276","authenticated-orcid":false,"given":"Shiori","family":"Kinoshita","sequence":"first","affiliation":[{"name":"Department of Clinical Oncology, Nagoya City University , Nagoya,","place":["Japan"]},{"name":"Department of Hematology and Oncology, Nagoya City University , Nagoya,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Takemoto","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Nagoya City University , Nagoya,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minami","family":"Asaoka","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Nagoya City University , Nagoya,","place":["Japan"]},{"name":"Department of Pharmacy, Nagoya City University , Nagoya,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko","family":"Haraguchi","sequence":"additional","affiliation":[{"name":"Department of Nursing, Nagoya City University , Nagoya,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamami","family":"Adachi","sequence":"additional","affiliation":[{"name":"Department of Nursing, Nagoya City University , Nagoya,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinsuke","family":"Iida","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Nagoya City University , Nagoya,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirokazu","family":"Komatsu","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Nagoya City University , Nagoya,","place":["Japan"]},{"name":"Department of Hematology and Oncology, Nagoya City University , Nagoya,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,9,17]]},"reference":[{"key":"2025010815265280100_ref1","doi-asserted-by":"publisher","first-page":"ofac064","DOI":"10.1093\/ofid\/ofac064","article-title":"Combination therapy with casirivimab\/imdevimab and remdesivir for protracted SARS-CoV-2 infection in B-cell-depleted patients","volume":"9","author":"Dioverti","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2025010815265280100_ref2","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1016\/j.annonc.2020.07.010","article-title":"Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus","volume":"31","author":"Curigliano","year":"2020","journal-title":"Ann Oncol"},{"key":"2025010815265280100_ref3","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1056\/NEJMsb2104756","article-title":"SARS-CoV-2 variants in patients with immunosuppression","volume":"385","author":"Corey","year":"2021","journal-title":"N Engl J Med"},{"author":"Centers for Disease Control and Prevention","key":"2025010815265280100_ref4"},{"key":"2025010815265280100_ref5"},{"key":"2025010815265280100_ref6","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1056\/NEJMc2031670","article-title":"Shedding of viable SARS-CoV-2 after immunosuppressive therapy for cancer","volume":"383","author":"Aydillo","year":"2020","journal-title":"N Engl J Med"},{"key":"2025010815265280100_ref7"},{"author":"Uzzo","key":"2025010815265280100_ref8","article-title":"COVID-19: Considerations in patients with cancer"},{"author":"Tara","key":"2025010815265280100_ref9","article-title":"COVID-19: Infection prevention for persons with SARSCoV-2 infection"},{"year":"2024","author":"Editorial committee of clinical management of COVID-19","key":"2025010815265280100_ref10"},{"key":"2025010815265280100_ref11","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.24296","article-title":"Factors associated with cancer treatment delay among patients diagnosed with COVID-19","volume":"5","author":"Mullangi","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2025010815265280100_ref12","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13756-022-01067-1","article-title":"Prolonged SARS-CoV-2 infection following rituximab treatment: clinical course and response to therapeutic interventions correlated with quantitative viral cultures and cycle threshold values","volume":"11","author":"Thornton","year":"2022","journal-title":"Antimicrob Resist Infect Control"},{"key":"2025010815265280100_ref13","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1093\/infdis\/jiab622","article-title":"Yearlong COVID-19 infection reveals within-host evolution of SARS-CoV-2 in a patient with B-cell depletion","volume":"225","author":"Nussenblatt","year":"2022","journal-title":"J Infect Dis"},{"key":"2025010815265280100_ref14","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1158\/2159-8290.CD-21-1033","article-title":"Prolonged SARS-CoV-2 infection in patients with lymphoid malignancies","volume":"12","author":"Lee","year":"2022","journal-title":"Cancer Discov"},{"key":"2025010815265280100_ref15","doi-asserted-by":"publisher","first-page":"ofab217","DOI":"10.1093\/ofid\/ofab217","article-title":"The longest persistence of viable SARS-CoV-2 with recurrence of viremia and relapsing symptomatic COVID-19 in an immunocompromised patient-a case study","volume":"8","author":"Sepulcri","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2025010815265280100_ref16","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1038\/s41375-021-01175-8","article-title":"Severe clinical relapse in an immunocompromised host with persistent SARS-CoV-2 infection","volume":"35","author":"Reuken","year":"2021","journal-title":"Leukemia"},{"key":"2025010815265280100_ref17","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41586-021-03291-y","article-title":"SARS-CoV-2 evolution during treatment of chronic infection","volume":"592","author":"Kemp","year":"2021","journal-title":"Nature"},{"key":"2025010815265280100_ref18","doi-asserted-by":"publisher","first-page":"ofab359","DOI":"10.1093\/ofid\/ofab359","article-title":"Defective severe acute respiratory syndrome coronavirus 2 immune responses in an immunocompromised individual with prolonged viral replication","volume":"8","author":"Gordon","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2025010815265280100_ref19","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1093\/infdis\/jiaa666","article-title":"Prolonged severe acute respiratory syndrome coronavirus 2 replication in an immunocompromised patient","volume":"223","author":"Baang","year":"2021","journal-title":"J Infect Dis"},{"key":"2025010815265280100_ref20","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1016\/j.cell.2020.10.049","article-title":"Case study: prolonged infectious SARS-CoV-2 shedding from an asymptomatic immunocompromised individual with cancer","volume":"183","author":"Avanzato","year":"2020","journal-title":"Cell"},{"key":"2025010815265280100_ref21","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1182\/blood.2021012251","article-title":"COVID-19 in patients with hematologic malignancy","volume":"140","author":"Langerbeins","year":"2022","journal-title":"Blood"},{"key":"2025010815265280100_ref22","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.ccell.2021.01.001","article-title":"Acute immune signatures and their legacies in severe acute respiratory syndrome Coronavirus-2 infected cancer patients","volume":"39","author":"Abdul-Jawad","year":"2021","journal-title":"Cancer Cell"},{"key":"2025010815265280100_ref23","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/bjh.17704","article-title":"COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies","volume":"195","author":"Passamonti","year":"2021","journal-title":"Br J Haematol"},{"key":"2025010815265280100_ref24","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1158\/2159-8290.CD-21-0191","article-title":"Preexisting and post-COVID-19 immune responses to SARS-CoV-2 in patients with cancer","volume":"11","author":"Bilich","year":"2021","journal-title":"Cancer Discov"},{"key":"2025010815265280100_ref25","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1265\/ehpm.23-00061","article-title":"Association between vaccination status and severe health consequences among community-dwelling COVID-19 patients during Omicron BA.1\/BA.2 and BA.5-predominant periods in Japan","volume":"28","author":"Tomioka","year":"2023","journal-title":"Environ Health Prev Med"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/55\/1\/80\/59144805\/hyae129.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/55\/1\/80\/59144805\/hyae129.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T15:27:02Z","timestamp":1736350022000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/55\/1\/80\/7758868"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,17]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,9,17]]},"published-print":{"date-parts":[[2025,1,8]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyae129","relation":{},"ISSN":["1465-3621"],"issn-type":[{"type":"electronic","value":"1465-3621"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2024,9,17]]}}}